Adma Biologics (ADMA) Capital Expenditures (2011 - 2025)

Adma Biologics' Capital Expenditures history runs 13 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Capital Expenditures fell 60.68% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 174.43% YoY) and the FY2025 annual result came in at $22.6 million, up 174.43% from the prior year.
• Capital Expenditures was $1.1 million for Q4 2025 at Adma Biologics, down from $14.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $14.4 million in Q3 2025 and bottomed at $757000.0 in Q3 2023.
• A 5-year average of $3.1 million and a median of $2.7 million in 2021 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 77.87% — and 2025, when it surged 1260.61%.
• Adma Biologics' Capital Expenditures stood at $3.7 million in 2021, then climbed by 1.98% to $3.7 million in 2022, then sank by 68.07% to $1.2 million in 2023, then surged by 130.33% to $2.8 million in 2024, then tumbled by 60.68% to $1.1 million in 2025.
• Business Quant data shows ADMA's Capital Expenditures at $1.1 million in Q4 2025, $14.4 million in Q3 2025, and $2.4 million in Q2 2025.